Charles Newton
Director of Finance/CFO chez LYELL IMMUNOPHARMA, INC.
Fortune : 108 276 $ au 31/03/2024
Profil
Charles Newton's current job(s) include serving as an Independent Director at Carmot Therapeutics, Inc. since 2023, at Coherus BioSciences, Inc. since 2022, at 2seventy Bio, Inc. since 2024, and as the Chief Financial Officer at Lyell Immunopharma, Inc. since 2021.
Formerly, Mr. Newton worked as a Managing Director at Morgan Stanley from 1996 to 2010, at BofA Securities, Inc., and as a Managing Director at Credit Suisse Group AG from 2010 to 2015.
Mr. Newton completed his undergraduate degree at Miami University and holds an MBA from the Tuck School of Business at Dartmouth.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
2SEVENTY BIO, INC.
0,03% | 20/03/2024 | 16 600 ( 0,03% ) | 88 810 $ | 31/03/2024 |
LYELL IMMUNOPHARMA, INC.
0,00% | 09/02/2024 | 8 729 ( 0,00% ) | 19 466 $ | 31/03/2024 |
| 07/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Charles Newton
| Sociétés | Poste | Début |
|---|---|---|
| LYELL IMMUNOPHARMA, INC. | Director of Finance/CFO | 01/02/2021 |
| COHERUS BIOSCIENCES, INC. | Director/Board Member | 05/05/2022 |
| 2SEVENTY BIO, INC. | Director/Board Member | 20/03/2024 |
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Director/Board Member | 19/07/2023 |
Anciens postes connus de Charles Newton
| Sociétés | Poste | Fin |
|---|---|---|
Credit Suisse Group AG /US/
 Credit Suisse Group AG /US/ Financial ConglomeratesFinance Credit Suisse Group AG /US/ engages in the provision of financial solutions. It offers services for private banking, investment banking, and asset management. The company is headquartered in New York, NY. | Chief Executive Officer | 01/11/2015 |
| MORGAN STANLEY | Corporate Officer/Principal | 01/09/2010 |
BofA Securities, Inc.
 BofA Securities, Inc. Investment Banks/BrokersFinance BofA Securities, Inc. is a registered broker-dealer subsidiary of NB Holdings Corp., ultimately held by Bank of America Corp. (NYSE: BAC). Headquartered in New York, the firm was founded in 2015 and offers trade execution, trading or brokerage services to institutional clients. | Corporate Officer/Principal | - |
Formation de Charles Newton
| Miami University | Undergraduate Degree |
| Tuck School of Business at Dartmouth | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| MORGAN STANLEY | Finance |
| COHERUS BIOSCIENCES, INC. | Health Technology |
| LYELL IMMUNOPHARMA, INC. | Health Technology |
| 2SEVENTY BIO, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Health Technology |
BofA Securities, Inc.
BofA Securities, Inc. Investment Banks/BrokersFinance BofA Securities, Inc. is a registered broker-dealer subsidiary of NB Holdings Corp., ultimately held by Bank of America Corp. (NYSE: BAC). Headquartered in New York, the firm was founded in 2015 and offers trade execution, trading or brokerage services to institutional clients. | Finance |
Credit Suisse Group AG /US/
Credit Suisse Group AG /US/ Financial ConglomeratesFinance Credit Suisse Group AG /US/ engages in the provision of financial solutions. It offers services for private banking, investment banking, and asset management. The company is headquartered in New York, NY. | Finance |
